|Title:|| Treatment of allograft rejection with mycophenolic acid morpholinoethylester and derivatives thereof|
|Abstract:||The compounds and pharmaceutical compositions of Formula A, wherein Z is hydrogen or --C(O)R, Y is hydrogen or morpholinoethyl, and where R is lower alkyl or aryl, and the pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, particularly for treatment of allograft rejection, especially including cardiac allograft rejection, pancreatic allograft rejection and renal allograft rejection, and for treating autoimmune diabetes. ##STR1##|
|Inventor(s):|| Allison; Anthony C. (Belmont, CA), Eugui; Elsie M. (Belmont, CA), Nelson; Peter H. (Los Altos, CA), Gu; Chee-Liang L. (Sunnyvale, CA), Lee; William A. (Palo Alto, CA) |
|Assignee:|| Syntex (U.S.A.) Inc. (Palo Alto, CA) |
|Filing Date:||Jan 22, 1988|
|Claims:||1. A method for treatment of allograft rejection in mammals, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound represented by the formula: ##STR8## wherein: Y is morpholinoethyl; and |
Z is hydrogen or --C(O)R,
where R is lower alkyl or aryl, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 comprising a method of treating cardiac allograft rejection, pancreatic allograft rejection or renal allograft rejection.
3. The method of claim 2 wherein Z is hydrogen.
4. The method of claim 1 wherein Z is hydrogen.